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1 Bioresonance therapy for allergy, atopic 
dermatitis, non-organic gastrointestinal 
complaints, pain and rheumatic diseases 
1.1 Background 
Bioresonance therapy was developed in the 1970’s by the physician Franz 
Morell in cooperation with the electrical engineer Erich Rasche. Bioreso-
nance therapy (BRT), or also called biophysical information therapy (BIT) 
derives from the electro-dermal testing according to Voll. BRT, as an alter-
native medical method is used for diagnosis and treatment of several dis-
eases like allergy, acute or chronic pain, rheumatic diseases and psychoso-
matic disorders [1]. 
BRT is based on the theory that bioelectro-magnetic fields exist, which 
cause oscillations and waves at a low frequency [2]. Furthermore, it is esti-
mated that these oscillations and waves are part of the information transmit-
ting system within the human body [3]. Only hypothetical explanations exist 
for these physical and physiological interactions. 
According to the proponents of the theory, the main purpose of BRT is to 
identify pathological waves within the human body and to give a strong im-
pulse to spontaneous healing energies of the body for self-regulation [2]. 
BRT is based on the assumption that atopic diseases disturb the normal 
electromagnetic fields of the body and that, through application of BRT/ 
BIT, these disturbances can be reversed [2].  
However, sceptics say that BRT is pure placebo, and that any effect must be 
caused by placebo or other non-specific effects [2, 4]. 
1.2 Description of treatment 
During the therapy there is a direct connection via two electrodes between 
the BRT apparatus and the patient. Depending on the purpose of the ther-
apy different forms of electrodes like cylinder, container, ball etc. are used. 
One of those two electrodes serves as the inline-electrode (or brass-electrode) 
which takes up waves and oscillations from one part of the body and trans-
mits them to the apparatus. Within the BRT machine there is a so-called 
“separator” which analyses the information from the brass-electrode and dis-
tinguishes supposedly between healthy and pathological waves. Then the 
separator reverses or “corrects” the pathological waves and oscillations into 
healthy ones and then they are transmitted back to the body via the second-
electrode, the “exit-electrode”. Usually the electrodes are connected with the 
extremities of the patient – either left or right side for the brass-electrode 
and the other one for the exit-electrode. 
The most widely used “bioresonance apparatuses” are the commercially 
available BICOM, MORA or Vegaselect machines [3]. 
Besides therapy, BRT is also used for diagnostic purposes, especially for di-
agnosis of allergies. There are up to 600 different allergens available for al-
developed in the 70’s 
based on the thesis that 
BRT gives impulses to 
spontaneous healing 
 
BRT is supported by 
apparatus that 
reverses/”corrects” 
pathological waves to 
healthy waves 
for therapy or diagnosis 
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lergy-testing. These allergens are either as biological active substances in 
ampoules or as software, where the information of the biological substances 
is digitally saved – also called electronic homeopathy [5] – obtainable [4]. 
The diagnostic procedure is similar to the therapy. Usually a cylindrical 
brass container electrode (inline electrode) is used to capture magnetic 
waves which are allegedly produced by allergens or other substances which 
might cause atopy and are then transferred through the BRT apparatus into 
the human body [2-3, 5]. 
1.3 Indication and therapeutic aim 
The indications covered in this review are pain, rheumatic diseases, atopic 
dermatitis, non-organic gastrointestinal complaints and allergies. 
The therapeutic aim is the alleviation or cure of these conditions.  
1.4 Treatment costs 
The costs of bioresonance treatment and diagnosis are not reported any-
where in the literature included in this review. 
 
allergy, atopic 
dermatitis, non-organic 
gastrointestinal 
complaints, pain and 
rheumatic diseases 
costs not reported 
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2 Literature search and selection 
2.1 PICO question 
Is bioresonance therapy effective in reducing pain, healing rheumatic dis-
eases, atopic dermatitis and allergies and in improving non-organic gastroin-
testinal complaints, in comparison to placebo or standard therapy? 
Is bioresonance therapy safe? 
2.2 Inclusion criteria 
Table 2.2-1: Inclusion criteria 
Population  Patients with pain. 
 Patients with rheumatic 
diseases. 
 Patients with non-organic 
gastrointestinal complaints. 
 Patients with allergies. 
 Patients with atopic derma-
titis. 
Intervention Bioresonance therapy and/ or diag-
nosis. 
Comparison Placebo or standard therapy. 
Outcomes Reducing and healing: 
 Allergy 
 Atopic dermatitis 
 Non-organic gastrointesti-
nal complaints 
 Pain 
 Rheumatic diseases. 
Study design All prospective studies with a control 
group. 
 
 
BRT effective in 
comparison to placebo 
or standard 
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2.3 Literature search 
The systematic literature search was carried out on 08.01.2009 in the follow-
ing databases: 
 Medline via Ovid 
 Embase 
 Cochrane library 
 CRD 
The search was limited to English and German language literature and cov-
ered the entire time span of the databases. 
After removal of duplicates, 56 bibliographical references were available. 
The exact strategy can be requested at the LBI for HTA. 
By means of a hand search, 1 additional reference was identified, which 
raised the overall number of hits to 57. 
The selection of the literature was carried out by two reviewers, independ-
ently of each other. Conflicting views were settled by means of discussion 
and consensus, or through the involvement of a third person. 
 
search in 4 databases 
57 references found, 6 
selected 
Literature search and selection 
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Full text articles: 
n = 14 
References excluded: 
n = 42 
Full text articles included: 
 
n = 6 
 
 2 RCTs 
 4 non-randomized, controlled trials 
Full text articles excluded: 
 
n = 8 
 
 2 Russian 
 1 case report 
 3 no control group 
 2 not a study 
 
Full text 
not available: 
n = 0 
Abstract pub-
lished only: 
n = 1 
Background 
literature: 
n = 0 
References identified by litera-
ture research:  
n = 57 
2.4 Literature selection 
 
 
Figure 2.4-1: Depiction of the selection process (QUORUM tree) 
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3 Assessment of the quality of the studies 
The evaluation of the quality of the studies was carried out by two reviewers, 
independently of each other. Conflicting views were settled by means of dis-
cussion and consensus, or through the involvement of a third person. An ex-
act list of the criteria that were used for the evaluation of the internal valid-
ity of the studies can be found in the internal manual of the LBI-HTA [6]. 
4 Data extraction 
The extraction of data was carried out by one person. A second person 
checked the completeness and accuracy of the data. 
4.1 Presentation of the study results 
Two RCTs and four non-randomized, controlled trials were included to an-
swer the question as to whether BRT is effective in reducing or healing al-
lergy, atopic dermatitis, non-organic gastrointestinal complaints, pain and 
rheumatic diseases and whether it is safe.  
 
assessment of quality of 
studies carried out by 
two reviewers 
extraction of data by 
one person 
two RCTs and four non 
randomized trials 
included for review 
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Table 4.1-1: Study results 
Author, Year, Ref-
erence number 
Kofler, H. et al. 1996 [4] Scho¨ni, M H. et al. 1997 
[2] 
Nienhaus, J. and Galle, 
M. 2006 [3] 
Schuller, J. and Galle, M. 
2007 [5] 
Bonetti, M. et al. 2007 
[7] 
Arena, M. et al. 2008 
[8] 
Country Innsbruck, Austria Switzerland Germany Austria Italy Italy 
Sponsor Firma Medtronic, 
Friesenheim, Germany 
supported by a grant 
provided by VOLG’s 
program “best friends”, 
Switzerland 
not reported not reported not reported not reported 
Study design non-randomized, con-
trolled trial 
RCT, sham-controlled, 
double-blind 
RCT, placebo controlled, 
single-blind patients 
(pts) 
non-randomized, pla-
cebo controlled trial, 
single-blind (pts) 
non-randomized con-
trolled trial 
non-randomized, con-
trolled trial 
Study quality good good moderate moderate fair fair 
Number of patients 74 (intervention (I): 54, 
control (C): 20) 
36 (I: 16, C: 16) 21 (I: 10, C: 10) 30 (not reported) 490 (I: 196, C: 294) 549 (A: 135, B: 139, C: 
137, D: 139) 
Lost to follow up 23 4 1 9 not reported not reported 
Study population pts diagnosed with hay 
fever who refused 
treatment with a spe-
cific hypo-sensitization 
therapy 
children with atopic 
dermatitis 
pts with non-organic 
gastro-intestinal com-
plaints 
pts with rheumatic dis-
eases 
pts with chronic uni-
lateral or bilateral low 
back pain 
pts with degenerative 
articular disease of the 
lumbar rachis with 
functional insuffi-
ciency of the vertebral 
motor unit 
O/ Patient age 
(years) 
not reported range 1.5-16.8 45.5 (range 13-82) 57.2 (range 40-82) 68 (range 55-87) range 50-75 
Indication for BRT hay fever, pollinosis  atopic dermatitis non-organic gastro-
intestinal complaints 
rheumatic disease chronic low back pain chronic low back pain 
Intervention biophysical allergy 
treatment with MORA 
bioresonance apparatus 
supplementary to con-
ventional medication 2 
treatment sessions 
weekly for at least 4 
weeks with bioreso-
nance apparatus BICOM 
II  
supplementary to con-
ventional medication 
treatment with MORA 
bioresonance apparatus 
treatment with MORA 
bioresonance apparatus 
4 weekly paraverte-
bral injections (10 cc 
of O2-O3 gas mixture 
at 25 μg/ml; outpa-
tient). BRT was given 
– supplementary – the 
month after infiltra-
tion 
comparison of 4 com-
binations of interven-
tions in back pain: 
A. TENS electro-sti-
mulation and psycho-
somatic postural re-
habilitation 
B. magneto-therapy of 
Data extraction 
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Author, Year, Ref-
erence number 
Kofler, H. et al. 1996 [4] Scho¨ni, M H. et al. 1997 
[2] 
Nienhaus, J. and Galle, 
M. 2006 [3] 
Schuller, J. and Galle, M. 
2007 [5] 
Bonetti, M. et al. 2007 
[7] 
Arena, M. et al. 2008 
[8] 
Control placebo placebo placebo placebo 4 weekly paraverte-
bral injections (10 cc 
of O2-O3 gas mixture 
at 25 μg/ml; outpa-
tient) only 
bioresonance, TENS 
electro-stimulation 
and psychosomatic 
postural rehabilitation 
C. percutaneous 
paravertebral infiltra-
tion of O2-O3, TENS 
electro-stimulation, 
psychosomatics pos-
tural rehabilitation 
D. percutaneous 
paravertebral infiltra-
tion of O2-O3, TENS 
electro- stimulation, 
psychosomatic pos-
tural rehabilitation, 
magneto-therapy of 
bioresonance 
Duration of treat-
ment 
4-6 weeks 4 weeks 3-6 weeks (6 treatment 
sessions per patient; 1-2 
per week) 
placebo: 2 weeks 
intervention: 4 weeks 
18 months  11 weeks (15 sessions 
each – first eight ses-
sions had a twice 
weekly schedule and 
weekly for the follow-
ing 7 sessions 
Main outcome 
measures 
congruence of conven-
tional allergological di-
agnostic and diagnostic 
with bioresonance; 
rhinomanometry and 
nasal provocation tests; 
individual calendar of 
complaints (duration of 
complaints in eyes, nose, 
bronchi) 
short term: clinical and 
skin scores (skin lesions/ 
Costa score/ itching/ 
pruritus score, sleep 
quality/ sleep score), 
blood cell activation 
marker 
pts’ and physicians’ es-
timation of the intensity 
and frequency of gastro-
intestinal disorders; ex-
amination results re-
corded by the physician: 
stomach pain by palpa-
tion, meteorism by per-
cussion and intestinal 
noise by auscultation as-
sessed pre and post 
treatment. 
EAP(electro acupunc-
ture)-40 value, subjec-
tive/ perceived state of 
health, biochemical, 
physicochemical  cellular 
parameters of blood 
modified MacNab 
Method:  
Excellent: resolution 
of pain and return to 
regular daily activity 
before pain onset 
good or satisfactory: 
more than 50% reduc-
tion of pain 
mediocre or poor: par-
tial reduction of pain 
below 70% 
scores of the VAS (Vis-
ual Analogic Scale) – 
pain evaluation scale 
(0-10; 0 = “no pain” 
and 10 = “the utmost 
pain”) 
Assessment times: 
prior/ after treatment, 
after 11 weeks of 
treatment & 1, 6 and 
12 months, respec-
tively. 
Bioresonance 
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Author, Year, Ref-
erence number 
Kofler, H. et al. 1996 [4] Scho¨ni, M H. et al. 1997 
[2] 
Nienhaus, J. and Galle, 
M. 2006 [3] 
Schuller, J. and Galle, M. 
2007 [5] 
Bonetti, M. et al. 2007 
[7] 
Arena, M. et al. 2008 
[8] 
Results congruence only in 
22%; 
repeated tests of rhino-
manometry and nasal 
provocation could not 
demonstrate any bene-
ficial effect compared to 
placebo  
change between scores 
prior treatment and af-
ter 4 weeks (total Costa 
Score): I: 39.8 ± 14.6 
→27.3 ± 13.1; C: 
35.3 ± 16.4 →26.6 ± 15.7; 
mean change I: 
12.5 ± 12.6; C: 6.7 ± 8.2. 
none of the differences 
between the groups was 
significant 
prior/ after treatment: 
significant changes in 
both groups (I:C) in all 
outcomes 
intensity/ frequency 
(pts’ estimation) 
I: 4.30 ± 0.30 → 2.20 ± 
1.05/ 4.40 ± 0.43 → 2.50 
± 0.94 vs. C: 3.70 ± 0.59  
→ 3.40 ± 0.52/ 4.20 ± 
0.64 → 3.80 ± 0.49 
(statistically significant 
changes between 
groups, Mann-Whitney-
U-Test, p<0.05); 
intensity/ frequency 
(physicians’ estimation) 
I: 3.30 ± 0.30 → 1.60 ± 
0.78/ 3.20 ± 0.49  → 
1.70 ± 0.83 vs. C: 3.60 ± 
0.32 → 3.30 ± 0.42/ 3.70 
± 0.42 → 3.60 ± 0.32 
(statistically significant 
changes between 
groups, Mann-Whitney-
U-Test, p<0,01); 
significant changes also 
for stomach pain & me-
teorism, but not for in-
testinal complaints 
EAP-changes prior/ after 
treatment: 
I: mean change of EAP-
40 -6.2 SkT (significant; 
p<0,05), 
C: -1.2 SkT  (not signifi-
cant; p<0.05)  
improvements in subjec-
tive outcomes 
 
I: 60%/ 21% (excel-
lent or good) vs. 
C: 52%/ 21% (excel-
lent or good) 
I: after period of im-
provement 21% par-
tial return of pain 
week 11: 
A-B: group A had 
more improvements 
than group B;  
B-C: group C main-
tained better thera-
peutic effects com-
pared to group B; 
C-D: group C and D 
are closely compara-
ble; singular effects of 
BRT were not meas-
ured 
Adverse events not reported none none not reported symptoms worsened 
in 9 pts 
not reported 
Data extraction 
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Author, Year, Ref-
erence number 
Kofler, H. et al. 1996 [4] Scho¨ni, M H. et al. 1997 
[2] 
Nienhaus, J. and Galle, 
M. 2006 [3] 
Schuller, J. and Galle, M. 
2007 [5] 
Bonetti, M. et al. 2007 
[7] 
Arena, M. et al. 2008 
[8] 
Conclusion of au-
thors 
no significant differ-
ences between interven-
tion-group and placebo-
group were found; the 
mean length of hay fe-
ver complaints were less 
in the placebo-group; 
the trial gives evidence 
that bioresonance is 
NOT suitable for diag-
nosis or treatment of 
pollinosis; the potential 
for placebo-effects is 
substantial; these pla-
cebo effects can be used 
– on an individual basis – 
as reasonable accompa-
nying measures 
scientific background of 
BRT seems to be rather 
shaky, for medical and 
ethical reasons, not pos-
sible to renounce con-
ventional medicine, only 
additional, no significant 
influence on atopic 
dermatitis, no side ef-
fects, but unethical to 
promise success 
BRT has significant 
mean effects, but big 
variances in individuals’ 
reactions: pts react indi-
vidually to an “all or 
nothing” principle; re-
sults of this trial confirm 
results of other trials 
when this effect (big 
variances in reactions) 
were observed 
limited number of pts 
involved, intervention 
and control group dif-
fered for ethical reasons, 
different length of 
treatment, therefore 
placebo effect likely to 
be underestimated, sin-
gle-blinded placebo ad-
ministration a “subtle 
form of suggestion” can 
not be out ruled; objec-
tivity, reliability and va-
lidity of EAP is under 
discussion 
preliminary findings 
show association with 
BRT, for pts with con-
traindications to drug 
treatment or in addi-
tion to medication, 
since no side effects 
are likely to occur 
caused by BRT 
the multi-disciplinary 
approach showed im-
provements in nearly 
all groups; the inte-
gration of TENS, bio-
resonance, postural 
rehabilitation guaran-
tees a better mainte-
nance over time 
Fair: placebo effect and reporting bias likely 
Moderate: some trial data not reported, outcome measures imprecise/ subjective 
Good: all patient data pre-/ post treatment reported, significant bias unlikely 
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4.2 Efficacy 
The populations that can be treated with BRT/ BIT vary. This is reflected in 
the very different indications treated in the trials included in this review. In 
the following paragraphs the efficacy of BRT/ BIT is evaluated for all of the 
5 indications listed in the PICO question – allergy, atopic dermatitis, non-
organic gastrointestinal complaints, rheumatic diseases and chronic low 
back pain. Altogether, the trials included 1210 patients. 
4.2.1 Efficacy of bioresonance therapy in diagnosis 
and treatment of allergy 
One [4] non-randomized, controlled-trial of good quality (n=74) reported on 
the efficacy of bioresonance therapy compared to standard care in diagnosis 
and treatment of allergy. Pollinosis was the type of allergy of interest in this 
placebo-controlled trial. Kofler et al. (1996) observed that only 22% of the 
results of conventional allergic diagnostic and diagnostic with bioresonance 
match. To measure the efficacy of bioresonance therapy rhinomanometry 
and nasal provocation tests were used. After the bioresonance treatment nei-
ther a significant difference to the start of the therapy nor between the ex-
perimental and the placebo group could be found considering these out-
comes. 
Based on the big variances within the results Kofler et al. (1996) concluded 
that bioresonance therapy is not superior to placebo and therefore not ade-
quate for diagnosis and treatment of allergic illnesses. Although, the meth-
odological quality of the trial is good the strength of evidence is rated mod-
erate, due to the small number of trials. 
4.2.2 Efficacy of bioresonance therapy in atopic 
dermatitis 
One RCT [2] of good quality (n=36) reported on the efficacy of bioreso-
nance therapy in children with atopic dermatitis. The trial was sham-
controlled and double-blind. Whereas the skin lesions (costa score) im-
proved significantly in both groups after 36 days, Schöni et al. (1997) found 
no significant difference between the experimental group and the placebo 
group. Similarly, the analysis of specific blood cell activation markers after 
the treatment period and the results of the questionnaire to assess long-term 
clinical outcomes 8 month after the therapy showed no significant changes 
in both groups. 
Further RCTs of good quality are required to establish the effect of BRT in 
atopic dermatitis, thus, although the quality of the study is good, the 
strength of evidence is rated moderate, due to small number of trials. 
 
5 indication groups 
diagnosis in only 22% 
congruence with 
conventional test 
no difference prior/ 
after therapy, nor 
between groups 
allergies 
BRT not effective 
mean: no difference; 
wide ranges between 
individuals 
BRT only additional 
small number of 
patients 
atopic dermatitis in 
children 
Data extraction 
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4.2.3 Efficacy of bioresonance therapy in non-
organic gastrointestinal complaints 
One RCT [3] of moderate quality (n=21) reported on the efficacy of biore-
sonance therapy in patients with non-organic gastrointestinal complaints. 
The trial was placebo-controlled and patients were blinded. In six out of 
seven main outcome parameters significant changes were observed in both 
groups prior/ after bioresonance therapy. The mean differences between ex-
perimental and placebo group were statistically significant. 
However, considerable variances within the intervention group were ob-
served, which reflects the results of other trials that patients react very indi-
vidually on the therapy. 
Further RCTs of good quality are needed to determine, whether BRT is ef-
fective in the treatment of non-organic gastrointestinal complaints. The 
strength of evidence is low, due to the small number of trials. 
4.2.4 Efficacy of bioresonance therapy in rheumatic 
diseases 
One [5] non-randomized, placebo-controlled, single-blind trial of moderate 
quality (n=30) reported on the efficacy of bioresonance therapy in rheu-
matic diseases. The main outcome measure was the EAP (electro acupunc-
ture)-40 value. Schuller & Galle (2007) found a significant improvement of 
the EAP-40 value in the intervention group (mean change -6.2 SkT) but not 
in the control group (-1.2 SkT). 
Although, the size of effect was high (0.69; possible values: 0-1) considerable 
variances between patients in the intervention group led to a very low stabil-
ity (0.16; possible values: 0-1) of the results within the group, which supports 
the findings of Nienhaus & Galle (2006). However, Schuller & Galle (2007) 
concluded that BRT is effective in the treatment of rheumatic diseases. 
Due to flaws in the methodological quality, like different duration of ther-
apy between placebo and experimental group of the study, results cannot be 
generalised. The strength of evidence is low, thus further RCTs of good 
quality are necessary to support the findings of this trial. 
4.2.5 Efficacy of bioresonance therapy in chronic 
low back pain 
Two [7-8] non-randomized, controlled-trials, both of fair quality (n=1039) 
and both conducted in Italy reported on the efficacy of BRT in chronic low 
back pain. Bonetti et al. (2007) and Arena et al. (2008) found the addition of 
BRT to therapy of chronic low back pain more effective than pain therapy 
alone. 
Bonetti et al. (2007) showed that the combination therapy of O2-O3 paraver-
tebral infiltration and BRT (experimental group) is more effective in treat-
ing chronic low back pain (81% excellent or good) compared to the control 
group (only oxygen-ozone therapy; 73% excellent or good). 
significant changes in 
both groups, but also 
between groups 
non-organic gastro-
intestinal complaints 
wide range between 
individual reactions 
 
10 patients received BRT 
rheumatic diseases 
significant differences 
between the groups 
wide range between 
individual reactions 
small number of 
patients – strength of 
evidence is low 
chronic low back pain 
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Arena et al. (2008) compared four different combinations of treatment op-
tions: percutaneous paravertebral infiltration of O2-O3, magneto-therapy of 
bioresonance (BRT), transcutaneous electrical nerve stimulation (TENS) 
and psychosomatic postural rehabilitation. Results of group D (combination 
therapy of all four treatment options – including BRT) were closely compa-
rable to the results of group C (not including BRT), which were both signifi-
cantly better than the results of group A and group B. Twelve month after 
the therapy the increasing pain was evaluated, thus group D (36.63% any-
vague; 27.72% considerable-grave) was superior to group C (28.57%; 43.88% 
respectively).  
The strength of evidence is low, thus further RCTs of good quality are 
needed to support the findings of Arena et al. (2008) and Bonetti et al. 
(2007). 
4.3 Safety 
Three [4-5, 8] out of the six included trials failed to make reference to the 
safety of BRT and two mentioned that no serious side effects occurred [2-3]. 
Bonetti et al. (2007) reported that the bioresonance therapy was generally 
well tolerated, whereas in nine patients symptoms worsened. Therefore they 
reduced the intensity of the treatment and concluded that the principle 
greater intensity results in greater efficacy is not always applicable in BRT. 
According to Nienhaus et al. (2006) up to now no serious side effects were 
reported in published human trials [3]. 
 
BRT shows additional 
effects but difference of 
questionable clinical 
relevance 
side effects are not 
mentioned as did not 
occur 
 LBI-HTA | 2009 19 
5 Strength of the Evidence 
The GRADE system is used to evaluate the strength of the evidence. 
GRADE uses the following classifications and definitions to evaluate the 
strength of the evidence (see [9]). 
 High: further research is very unlikely to change our confidence in 
the estimate of effect 
 Moderate: Further research is likely to have an important impact on 
our confidence in the estimate of effect and may change the estimate 
 Low: Further research is very likely to have an important impact on 
our confidence in the estimate of effect and is likely to change the es-
timate 
 Very low: any estimate of effect is very uncertain 
 
GRADE system 
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Table 5-1: Evidence profile of bioresonance therapy 
Number of 
studies/ patients 
Design Methodological 
quality 
Consistency of re-
sults 
Directness Size of effect Other modi-
ficatory fac-
tors 
Strength of 
the collective 
evidence 
Outcome: allergy – pollinosis (hay fever) 
1/74 non-randomized, 
controlled trial 
good not applicable* yes congruence of diagnosis in 22%; as the therapy is 
based on the diagnosis, the use of BRT cannot be 
effective 
none moderate 
Outcome: atopic dermatitis in children 
1/36 RCT, sham-
controlled, double-
blind 
good not applicable yes 9.6 ± 10.8 (Wilcoxon signed rank test; p<0.001) 
mean reduction in Costa score, no significant dif-
ferences between treatment and placebo 
none moderate 
Outcome: non-organic gastrointestinal problems 
1/21 RCT, placebo-
controlled, single-
blind (pts) 
moderate not applicable yes significant changes prior/ after treatment in both 
groups (pts’ estimation I: 4.30 ± 0.30 → 2.20 ± 1.05 
vs. C: 3.7 ± 0.59 → 3.40 ± 0.52); statistically 
(Mann-Whitney-U-Test) significant difference be-
tween groups, but of questionable clinical rele-
vance 
none low 
Outcome: rheumatic disease 
1/30 non-randomized, 
placebo-controlled 
trial, single-blind 
(pts) 
moderate not applicable yes I: -6.2 SkT mean reduction with very low stability 
between pts (range 3.8-18.4 SkT); statistically sig-
nificant (p<0.05) 
C: -1.2 SkT mean reduction; statistically not signifi-
cant (p<0.05) 
none low 
Outcome: chronic low back pain 
2/1039 non-randomized, 
controlled trial 
fair yes yes BRT in addition to other non-drug therapies shows 
additional benefit 
none low 
*applicable only if more than one study 
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6 BICOM – commissioned report 
Additionally to the in Chapter 3 analysed trials we received two reports [10-
11] summarizing trials evaluating the effectiveness of BRT. Most of the in-
cluded trials are published in Chinese language, were a conference presenta-
tion or a research report in a language other than German or English, which 
didn’t make it possible for us to critically appraise the originally published 
study reports. 
Both reports on the clinical effectiveness of BRT were conducted as a com-
missioned work from Regumed GmbH, the producer of the BICOM bioreso-
nance apparatus, by the biometrician Dr. Volker W. Ralphs (2005) and V. 
W. Ralphs  in cooperation with the physician Dr. med. Andreas Rozehnal 
(2006). Their analysis included 15 trials provided to them by the company 
Regumed. They graded the “Level of evidence” according to the scheme of 
the American Heart Association (modified according to Dick 2000). 
As our systematic review only included prospective and controlled trials we 
will only summarize the result of studies graded “evidence level 1-3” (8 evi-
dence levels; 1=highest, 8=lowest). 
Thus, we took the following five trials into consideration:  
 Yang J and Zhang L., 2004 [12]. They examined whether treatment 
of asthmatic patients with BRT is superior to conventional treat-
ment with corticoids and antiallergics. Therefore, they designed a 
prospective and controlled trial with 300 patients (children) (I: 213; 
C: 87) and compared the outcomes differentiating between “heal-
ing”, “improvement”, “effective”, “not effective” after six month. 
Whereas 43.8% of the intervention group reported “healing”, 42.5% 
of the control group did so; “improvement” (I: 31.9%; C: 19.5%); 
”effective” (I: 11%; C: 13.8%) and ”not effective” (I: 13.3%; C: 
24.2%). 
 Huang S. et al., 2005 [13]. Huang S. et al. conducted a RCT to find 
out whether BRT is effective in treating children with allergic 
asthma and allergic rhinitis. The 181 patients recruited were di-
vided in 3 groups: (1) BICOM bioresonance treatment for children 
with first diagnosis of the disease, (2) BICOM bioresonance treat-
ment in children who did not respond to prior medical treatment 
and (3, control group) children with first diagnosis, no prior treat-
ment and medical treatment with glucocorticoids and antihista-
mine. After six month they evaluated the effectiveness with a three-
point-scale: “considerably effective”, “effective” and “ineffective”. 
The clinical effectiveness of BRT in allergic rhinitis (considerably 
effective and effective) in group 1 (85.4%) and group 2 (81.9%) is 
not significantly better than conventional medical treatment (group 
3: 78.1%) (p>0.05); comparable results for allergic asthma – (1) 
86.4%, (2) 78.1% and (3) 76%. Although the authors conclude that 
this therapy is considerably suitable for patients with chronic dis-
ease because they are equally effective as conventional therapy and 
do not cause severe adverse effects like some medications. 
 Machowinski R. & Gerlach I., 1996 [14]. They examined whether 
BRT is clinically effective in treating patients with impairment of 
hepatocytes in comparison not to do anything. According to the 
additional source: 
BICOM commissioned  
report including mostly 
Chinese publications 
only two controlled 
trials 
asthma in children 
 
small effects in 
improvement 
asthma/ rhinitis 
equally effective to 
conventional therapy 
impairment of 
hepatocytes 
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commissioned report differences between groups were statistically 
significant and clinically relevant. Unfortunately, no data to sup-
port these findings are provided in the commissioned report. 
 Papez B. and Barovic, n.a.[15]. According to Papez and Barovic’s 
research paper the purpose of the trial was to examine whether 
treatment with BRT (I: 12 pts) is superior to ultrasound therapy (C: 
12 pts) in overload syndrome in top athletes. The main clinical out-
come measure was the VAS-pain score (0-10). The means of the in-
tervention group improved significantly prior/ after therapy. Fur-
ther, BRT was statistically significant and clinically relevant supe-
rior to ultrasound therapy (p<0.05). 
 Giannazo E. et al., 2002 [16]. This trial was conducted to validate 
the allergy-diagnosis procedure with the BICOM apparatus com-
pared to the standard test – the “Prick-test”. Each of the 31 patients 
included was tested in the same four indications with both meth-
ods. The sensitivity of the BICOM-test was found to be 0.84 (95% 
CI: 0.72-0.91) and the specificity was 0.66 (95% CI: 0.53-0.78). Sen-
sitivity and specificity of the “Prick-test” were not reported. Gian-
nazo et al. (2002) concluded that BRT diagnosis is clinically rele-
vant because it is superior to “guessing”. 
Due to considerable methodological flaws two of the provided trials were ex-
cluded from the summary of the evidence by the authors. Ralphs and Roz-
henal (2006) concluded based on the other six trials – Huang S. et al. (2005) 
level 1-2, Yang J. and Zhang L. (2004) level 2-3 and the remaining 4 were 
graded with level 5 – that these findings clearly show that BRT is effective in 
allergy. Further, Ralphs (2005) concluded that BRT is also clinically effec-
tive in treating impairment of hepatocytes and top athletes with overload 
syndrome. 
 
significant differences 
between groups – no 
data available 
overload syndrome in 
top athletes 
BRT superior to 
ultrasound therapy 
BICOM diagnosis vs. 
Prick-test 
specificity and 
sensitivity 
BRT effective in treating 
allergy, impairment of 
hepatocytes and 
overload syndrome 
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7 Discussion and Conclusion 
The evidence of Bioresonance therapy is very heterogeneous. Overall, trial 
results show big placebo effects and big variances between patients. There-
fore, authors of the trials included suggest that BRT should only be provided 
additionally to standard of care and after detailed education on effectiveness 
of BRT of the patient. 
As therapy bases on the right diagnosis, BRT is not suitable for diagnosis 
and not for therapy of allergy in patients with pollinosis. The placebo-effect 
in the treatment of children with atopic dermatitis is estimated high as 
treatment and placebo group show significant improvements while the dif-
ferences between the groups were not statistically significant. Although the 
difference between means of placebo and intervention group was statistically 
significant in non-organic gastrointestinal complaints and in rheumatic dis-
eases, high placebo-effects are assumed due to wide ranges between individ-
ual reactions. Using BRT in combination with other treatment options for 
chronic low back pain showed additional effect in the improvement of symp-
toms. 
Finally, providing BRT to patients and promising unforeseeable results is 
also an ethical question. The wide possible variances between individuals 
have to be communicated to the patients. Thus, further RCTs of good qual-
ity are needed to clarify how BRT works and in which indications it is effec-
tive. 
 
heterogeneous evidence 
 
 
 
 
 
high placebo effects and 
big variances between 
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